NCT07894640
Clinical Safety and Efficacy Evaluation of the Blood-cooling and Stasis-removing Formula as an Adjunct to Atorvastatin in the Treatment of Hemorrhagic Moyamoya Disease.
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 1 version: 1 with changes below.
- Study First Submitted
Endpoints
Primary
Secondary (7)
Show 2 moreShow less
Arms and interventions
Based on standard Western medicine treatment (as placebo comparator), a modified version of the blood-cooling and stasis-removing formula (200ml per dose, twice a day, one dose each time, a formula agreed upon by Nanjing Municipal Hospital of Traditional Chinese Medicine)+Lipid-lowering drug (atorvastatin, Pfizer, 10mg, one tablet once a day) was used for treatment.
Standard Western medical treatment was administered. Upon diagnosis, vital signs were immediately monitored, and imaging examinations including a head CT scan, complete blood count, comprehensive biochemistry panel, and coagulation function tests were completed. Routine Western medical intervention was given, including lipid-lowering drugs (atorvastatin, Pfizer, 10mg once daily, one tablet). A placebo was added accordingly. The placebo was prepared by mixing 10% of the original drug formula with rice and edible flavoring to create a control placebo with similar color, taste, and properties.
Drugs: Atorvastatin, Blood-cooling and Stasis-clearing Formula, Blood-cooling and Stasis-clearing Formula Placebo
Sites
1 site in 1 country
- Jiangsu Province Hospital (Jiangsu Provincial People's Hospital)Nanjing, Jiangsu, China